In vitro transdermal delivery of caffeine, theobromine, theophylline and catechin from extract of Guarana, Paullinia Cupana

被引:50
作者
Heard, Charles M. [1 ]
Johnson, Sarah
Moss, Gary
Thomas, Chris P.
机构
[1] Univ Cardiff Wales, Welsh Sch Pharm, Cardiff CF10 3XF, Wales
[2] Univ Hertfordshire, Sch Pharm, Hatfield AL10 9AB, Herts, England
关键词
Paullinia cupana; Guarana; transdermal; patch; skin; theobromine; theophylline; (+)-catechin; caffeine;
D O I
10.1016/j.ijpharm.2006.02.042
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Extracts of guarana (Paullinia cupana) feature as putatively stimulating ingredients in a number of foods, drinks and dietary/herbal supplements. The objective of this work was to investigate in vitro the transdermal delivery of the major pharmacologically active compounds contained in guarana extract. Saturated solutions of guarana were prepared in polyethylene glycol 400 (PEG400), propylene glycol (PG) and H2O at 32 degrees C. Guarana extract was also formulated in Duro-tak (R) 2287 transdermal adhesive in a range of concentrations and the diffusional release was determined in addition to adhesive properties. Transdermal delivery across full thickness pig ear skin was investigated in vitro using Franz-type diffusion cells, with reverse-phase HPLC being used for the quantification of the permeation of theobromine (TB), theophylline (TP), (+)-catechin (C) and caffeine (CF). Based upon a combination of release and adhesive property data a patch containing 5.55 mg guarana extract cm(-2) was deemed optimal. The general trend for the delivery of the 4 analytes was: water > 5.55 mg cm(-2) patch approximate to PG > PEG400. For CF the greatest steady state flux was obtained from the water vehicle: 19 mu g cm(-2) h(-1), with similar to 420 mu g cm(-2) permeating after 24 h. This was some 6 x times more than from the drug-in-adhesive patch and 10x greater than PG, a well-known penetration enhancer, and 50x that of the 'regular' excipient PEG400. A water vehicle also provided the greatest delivery of TB (0.45 mu g cm(-2) h(-1)), TP (0.022 mu g cm(-2) h(-1)), and C (0.10 mu g cm(-2) h(-1)). An inverse relationship was noted between lipophilicity and k(p) in each vehicle. The simultaneous transdermal delivery of the major actives of guarana was established, with permeation rates being highly concentration and vehicle dependent. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 19 条
[1]
Antibacterial and antioxidant activities of ethanol extract from Paullinia cupana Mart. [J].
Basile, A ;
Ferrara, L ;
Del Pezzo, M ;
Mele, G ;
Sorbo, S ;
Bassi, P ;
Montesano, D .
JOURNAL OF ETHNOPHARMACOLOGY, 2005, 102 (01) :32-36
[2]
In vitro transdermal delivery of the major catechins and caffeine from extract of Camellia sinensis [J].
Batchelder, RJ ;
Calder, RJ ;
Thomas, CP ;
Heard, CM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 283 (1-2) :45-51
[3]
LIMITATIONS OF HAIRLESS MOUSE SKIN AS A MODEL FOR INVITRO PERMEATION STUDIES THROUGH HUMAN-SKIN - HYDRATION DAMAGE [J].
BOND, JR ;
BARRY, BW .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1988, 90 (04) :486-489
[4]
Film drying and complexation effects in the simultaneous skin permeation of ketoprofen and propylene glycol from simple gel formulations [J].
Bowen, JL ;
Heard, CM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 307 (02) :251-257
[5]
Carlson M, 1998, J AOAC INT, V81, P691
[6]
Threshold level for theophylline in doping analysis [J].
Delbeke, FT ;
DeBacker, P .
JOURNAL OF CHROMATOGRAPHY B, 1996, 687 (01) :247-252
[7]
DULLOO AG, 1993, INT J OBESITY, V17, pS35
[8]
Pharmacological activity of Guarana (Paullinia cupana Mart) in laboratory animals [J].
Espinola, EB ;
Dias, RF ;
Mattei, R ;
Carlini, EA .
JOURNAL OF ETHNOPHARMACOLOGY, 1997, 55 (03) :223-229
[9]
Effects of membrane type and liquid/liquid phase boundary on in vitro release of ketoprofen from gel formulations [J].
Gallagher, SJ ;
Trottet, L ;
Carter, TP ;
Heard, CM .
JOURNAL OF DRUG TARGETING, 2003, 11 (06) :373-379
[10]
Short-term metabolic and hemodynamic effects of ephedra and guarana combinations [J].
Haller, CA ;
Jacob, P ;
Benowitz, NL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (06) :560-571